Online inquiry

IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6987MR)

This product GTTS-WQ6987MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pagA gene. The antibody can be applied in Anthrax research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_000746486.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 45025512
UniProt ID P13423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6987MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8355MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ13205MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ8441MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ8858MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ4835MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ8611MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ12232MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW